Navigation Links
Senesco Appoints Harlan W. Waksal, M.D., to Board of Directors
Date:10/29/2008

Co-founder of and Former Senior Executive at ImClone Brings Substantial Oncology Drug Development Expertise

NEW BRUNSWICK, N.J., Oct. 29 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Alternext US: SNT) announced today the appointment of Harlan W. Waksal, M.D., 55 to its board of directors. Senesco's board of directors now consists of nine members, seven of whom are independent.

(Photo: http://www.newscom.com/cgi-bin/prnh/20081029/NY42202 )

Dr. Waksal is the President and Sole Proprietor of Waksal Consulting L.L.C., which was founded in 2003 and provides strategic business and clinical development counsel to biotechnology companies. Dr. Waksal co-founded the biotechnology company, ImClone Systems Incorporated, in 1984. He served at ImClone in a variety of senior roles over a 16 year period, beginning in 1987. During his tenures as Chief Operating Officer, from 1987 through 2002, and Chief Executive Officer, from 2002 until 2003, Dr. Waksal was instrumental in moving forward the clinical development program for ERBITUX(R) (cetuximab), an oncology drug now approved in colorectal and head & neck cancers. ERBITUX (cetuximab) is a monoclonal antibody (IgG1 Mab) designed to inhibit the function of a molecular structure expressed on the surface of normal and tumor cells, called the epidermal growth factor receptor (EGFR).

"Senesco is very pleased to have Dr. Waksal join our Board," said Rudolf Stalder, Chairman of Senesco's Board. "His significant contribution to the clinical development of Erbitux, and vast knowledge of the oncology space, will provide critical industry insight to Senesco."

"We look forward to working with Dr. Waksal as we move toward our goal of filing an IND for multiple myeloma," said Bruce Galton, President & Chief Executive Officer of Senesco. "We believe his extensive and distinguished wo
'/>"/>

SOURCE Senesco Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Senescos Preclinical Multiple Myeloma Data to be Presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
2. Senesco Technologies Announces Successful Completion of First Milestone Related to Agreement with Bayer CropScience
3. Senesco Technologies Closes Remaining $3.0 Million of Previously Announced Financing
4. Senesco Signs a Supply Agreement for Polyplus-transfections Delivery System
5. Senesco Technologies to Present at BIO 2008 Business Forum
6. Senesco Technologies Reports Third Quarter Fiscal 2008 Financial Results
7. Senesco Technologies Regains Compliance With Amexs Continued Listing Requirements
8. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
9. Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies
10. Senesco Technologies Closes on Additional $4.0 Million of Previously Announced Financing
11. Boston Healthcare Appoints Adam Barak as Vice President Enhancing Its International Pricing and Reimbursement Capability
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014  Sigma-Aldrich Corporation (NASDAQ: ... energy use, increased its investment in Green Chemistry and ... the world last year, the Company announced Monday in ... Science Changed the World? The report ... honors for being a responsible corporate citizen, including recognition ...
(Date:7/29/2014)... SPRING, Md., July 29, 2014  United Therapeutics ... announced its financial results for the second ... continued growth shows that our medicines are ... pulmonary arterial hypertension (PAH)," said Martine Rothblatt, ... Officer. "The commercial launch this quarter of ...
(Date:7/29/2014)... July 29, 2014 Eppendorf Centrifuge ... product selection. Eppendorf 5427 R is geared towards high-end ... – it is targeted towards work requiring high sample ... R as it compliments their extensive 16, 48, and ... of microcentrifuge tubes, PCR tubes, PCR strip tubes, and ...
(Date:7/29/2014)... 29, 2014 White papers by ... cloud based eClinical technologies, have been published by leading ... follow a long line of white papers by Clinovo ... Life Science Leader, Pharmaceutical Online, and OpenHealthNews. , At ... paper by CTO Marc Desgrousilliers, 'The Five Essentials ...
Breaking Biology Technology:Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 2Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 11United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 12United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 13International Pipette Distributor, Pipette.com Announces the Addition of the Eppendorf Centrifuge 5427 R to Their Product Portfolio 2Clinovo White Papers Published in Summer 2014 Editions of Leading Medical Device & Pharmaceutical Publications 2Clinovo White Papers Published in Summer 2014 Editions of Leading Medical Device & Pharmaceutical Publications 3
... Support Fund,s Goal of Finding a Cure for ... Animal Health and the National,Thoroughbred Racing Association (NTRA) ... the NTRA Charities - Barbaro Memorial Fund. The,partnership,s ... across the horse,industry and encourage further support of ...
... Novinski to Discuss Plans for Company in 2008 ... 31 Emisphere,Technologies, Inc. (Nasdaq: EMIS ), ... Thursday, February 7, at 10:00 AM EST. President ... the company,s,emerging business strategy. Emisphere is a biopharmaceutical ...
... Board of Directors, SAN DIEGO, Jan. 31 ... therapeutics for the,treatment of Alzheimer,s disease, announced today ... A round of financing. The financing was led ... Partners. Additional,investors included AgeChem Venture Fund, and MC ...
Cached Biology Technology:Pfizer Animal Health and NTRA Charities Team Up to Benefit the Barbaro Memorial Fund 2Emisphere to Host Business Strategy Conference Call on February 7 2Emisphere to Host Business Strategy Conference Call on February 7 3Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimer's Treatments 2Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimer's Treatments 3
(Date:7/29/2014)... has received from the National Institutes of Health ... project to support the further development of 23andMe,s ... , Specifically, the grant supports four areas ... to improve the company,s ability to identify novel ... to support the collection of a broader set ...
(Date:7/29/2014)... preterm babies latest research from the University of ... the brains of many preterm children can perform almost as ... by the University,s Robinson Research Institute has found ... injury in early life, their cognitive abilities as a teenager ... However, the results of the study, published in this month,s ...
(Date:7/29/2014)... disease it affects 1 in 100,000 people characterized ... While its cause remains unknown, a new study by a ... of Bonn in Germany and other European institutions confirms for ... study, published on 6 July in Nature Genetics , ... When we swallow, a sphincter in the lower esophagus opens, ...
Breaking Biology News(10 mins):23andMe scientists receive approximately $1.4 million in funding from National Institutes of Health 223andMe scientists receive approximately $1.4 million in funding from National Institutes of Health 3Preterm children's brains can catch up years later 2Mysterious esophagus disease is autoimmune after all 2
... Yukon River Basin provide unique insights on climate change ... local communities. The USGS coordinated interviews with ... Mary,s and Pitka,s Point, Alaska, to document their observations ... such as unpredictable weather patterns and dangerous ice conditions, ...
... unlocked a mechanism behind the way short- and long-term motor ... research from a team led by Nicolas Schweighofer of ... could potentially pave the way to more effective rehabilitation for ... motor memory is actually the product of two processes: short-term ...
... Andrea Endimiani, M.D., Ph.D., Institute of Veterinary ... by the American Society for Microbiology (ASM) to ... combining basic microbiology, epidemiology, pharmacology, biochemistry, and molecular ... traits on the outcome of infections caused by ...
Cached Biology News:Observations of climate change from indigenous Alaskans 2Observations of climate change from indigenous Alaskans 3Motor memory: The long and short of it 2The American Society for Microbiology honors Andrea Endimiani 2The American Society for Microbiology honors Andrea Endimiani 3
...
Performance, mycoplasma, virus, and endotoxin tested. Collected from calves 14 days old or less...
...
Mus musculus junctophilin 2 (Jph2) Antigen: Recombinant Protein...
Biology Products: